Allergy Therapeutics (LON:AGY) Stock Price Up 11.1% – Should You Buy?

Allergy Therapeutics plc (LON:AGY) was up 11.1% during trading on Thursday . The stock traded as high as GBX 10 and last traded at GBX 10. Approximately 578,138 shares were traded during trading, an increase of 92% from the average daily volume of 300,673 shares. The stock had previously closed at GBX 9.

Allergy Therapeutics Price Performance

The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The stock’s 50 day moving average price is GBX 11.24 and its two-hundred day moving average price is GBX 9.52. The stock has a market cap of £614.14 million, a price-to-earnings ratio of -11.90, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings results on Monday, February 16th. The company reported GBX (0.84) EPS for the quarter. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%. Equities research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.